Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 5/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | USP1 | O94782 | 1/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.31 |
| ▸ | TPH1 | P17752 | 1/20 | 0.31 |
| ▸ | TPH2 | Q8IWU9 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2471363 | 0.95 | GRIN1 (0.39) | GRIN1GRIN2BMEN1ALDH1A1CYP3A4 | |
| SCHEMBL2471911 | 0.95 | GRIN1 (0.39) | GRIN1GRIN2BMEN1ALDH1A1CYP3A4 | |
| SCHEMBL2469750 | 0.94 | GRIN1 (0.38) | GRIN1GRIN2BMEN1ALDH1A1CYP3A4 | |
| SCHEMBL7070555 | 0.92 | GRIN1 (0.35) | GRIN1GRIN2BMEN1ALDH1A1CYP3A4 | |
| SCHEMBL7851616 | 0.88 | GRIN1 (0.34) | GRIN1GRIN2BMEN1ALDH1A1CYP3A4 | |
| SCHEMBL2469085 | 0.84 | HPGD (0.39) | GRIN1GRIN2BMEN1ALDH1A1KMT2A | |
| SCHEMBL7072203 | 0.83 | PKM (0.30) | — | |
| SCHEMBL6087415 | 0.82 | GRIN1 (0.43) | GRIN1GRIN2BMEN1ALDH1A1CYP3A4 | |
| SCHEMBL6086546 | 0.82 | TPH1 (0.34) | GRIN1GRIN2BMEN1ALDH1A1KMT2A | |
| SCHEMBL7073641 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1986651-B1 | USE OF A PYRIMIDINEDIONE DERIVATIVE FOR PREVENTING OR TREATING HEPATITIS C | SAMJIN PHARM CO LTD (KR) | 2011-10-05 | — | — | EP | claimed |
| US-7851479-B2 | Use of pyrimidinedione derivative for preventing or treating hepatitis C | SAMJIN PHARM. CO., LTD. (KR) | 2010-12-14 | — | — | US | claimed |
| US-20090023764-A1 | Use of Pyrimidinedione Derivative for Preventing or Treating Hepatitis C | SAMJIN PHARM. CO., LTD. (KR) | 2009-01-22 | — | — | US | claimed |
| EP-1986651-A1 | USE OF A PYRIMIDINEDIONE DERIVATIVE FOR PREVENTING OR TREATING HEPATITIS C | Samjin Pharmaceutical Co., Ltd. (KR) | 2008-11-05 | — | — | EP | claimed |
| WO-2007091857-A1 | USE OF A PYRIMIDINEDIONE DERIVATIVE FOR PREVENTING OR TREATING HEPATITIS C | SAMJIN PHARM. CO., LTD. (KR) | 2007-08-16 | — | — | WO | claimed |
| EP-1986651-B1 | USE OF A PYRIMIDINEDIONE DERIVATIVE FOR PREVENTING OR TREATING HEPATITIS C | SAMJIN PHARM CO LTD (KR) | 2011-10-05 | — | — | EP | disclosed |
| US-7851479-B2 | Use of pyrimidinedione derivative for preventing or treating hepatitis C | SAMJIN PHARM. CO., LTD. (KR) | 2010-12-14 | — | — | US | disclosed |
| US-7851479-B2 | Use of pyrimidinedione derivative for preventing or treating hepatitis C | SAMJIN PHARM. CO., LTD. (KR) | 2010-12-14 | — | — | US | disclosed |
| US-7851479-B2 | Use of pyrimidinedione derivative for preventing or treating hepatitis C | SAMJIN PHARM. CO., LTD. (KR) | 2010-12-14 | — | — | US | disclosed |
| US-20090023764-A1 | Use of Pyrimidinedione Derivative for Preventing or Treating Hepatitis C | SAMJIN PHARM. CO., LTD. (KR) | 2009-01-22 | — | — | US | disclosed |
| US-20090023764-A1 | Use of Pyrimidinedione Derivative for Preventing or Treating Hepatitis C | SAMJIN PHARM. CO., LTD. (KR) | 2009-01-22 | — | — | US | disclosed |
| US-20090023764-A1 | Use of Pyrimidinedione Derivative for Preventing or Treating Hepatitis C | SAMJIN PHARM. CO., LTD. (KR) | 2009-01-22 | — | — | US | disclosed |
| US-6987114-B1 | Antiviral pyrimidinedione derivatives and process for the preparation thereof | SAMJIN PHARMACEUTICAL CO., LTD (KR) | 2006-01-17 | — | — | US | disclosed |
| EP-1100786-B1 | ANTIVIRAL PYRIMIDINEDIONE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | SAMJIN PHARM CO LTD (KR) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023764-A1 | Use of Pyrimidinedione Derivative for Preventing or Treating Hepatitis C | DPYD, UMPS, TYMP | GRIN1 3565/4885GRIN2B 4208/4885MEN1 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.